DBV Technologies (DBV)

8.55
-0.54(-5.90%)
  • Volume:
    613,006
  • Bid/Ask:
    0.00/0.00
  • Day's Range:
    8.47 - 9.07
  • Type:Equity
  • Market:France
  • ISIN:FR0010417345

DBV Overview

Prev. Close
9.09
Day's Range
8.47-9.07
Revenue
16.77M
Open
9.02
52 wk Range
2.35-13.69
EPS
-2.48
Volume
613,006
Market Cap
469.9M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
290,147
P/E Ratio
-
Beta
1.84
1-Year Change
27.61%
Shares Outstanding
54,933,812
Next Earnings Date
Oct 26, 2021
What is your sentiment on DBV Technologies?
or
Market is currently closed. Voting is open during market hours.

DBV Technologies News

DBV Technologies Analysis

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesSellSellStrong SellStrong SellStrong Sell
Technical IndicatorsSellSellStrong SellStrong SellNeutral
SummarySellSellStrong SellStrong SellSell

DBV Technologies Company Profile

DBV Technologies Company Profile

Employees
104
Market
France

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents, and adults. The company is also developing Viaskin Milk that is in Phase I/II clinical trial for the treatment of Immunoglobulin E (IgE) mediated cow’s milk protein allergy (CMPA) and milk-induced eosinophilic esophagitis; Viaskin Egg, a pre-clinical stage product for the treatment of hen’s egg allergy; and booster vaccine for Bordetella pertussis. Its other earlier stage research programs include a vaccine for the respiratory syncytial virus, as well as treatments for Crohn’s disease, celiac disease, and type I diabetes. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was founded in 2002 and is headquartered in Montrouge, France.

Read More
  • https://finance.yahoo.com/news/notice-media-covid-19-july-120000875.html?.tsrc=fin-srch
    0
    • FDA will approve it...
      0
      • DBV Technologies price target raised to $7 from $4 at Goldman Sachs. Goldman Sachs analyst Graig Suvannavejh raised the firm's price target on DBV Technologies (DBVT) to $7 from $4 and keeps a Buy rating on the shares after the company announced an update on the U.S. regulatory status of lead asset Viaskin Peanut. The stock closed Friday up 51% to $5.66. The analyst came away "increasingly positive" given the clarity gained on the forward, and continues to have confidence in the ultimate approvability of Viaskin Peanut in the U.S. and its commercial potential. Viaskin Peanut is the more attractive and easier product to administer relative to its main competition, Nestle's (NSRGY) Palforzia, Suvannavejh tells investors in a research note.
        0
    Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
    Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.